Market Overview

UPDATE: JP Morgan Raises PT to $31 on Pfizer Following Q4 Results, Guidance

Share:
Related PFE
The Current State Of The Breast Cancer Treatment Space
Exclusive: Corium CEO Gives The Scoop On His Company's Latest Alzheimer's Data
IBD 50 Stock Veeva Flies To Record High On 'Another Exceptional Quarter' (Investor's Business Daily)

JP Morgan maintained Pfizer, Inc. (NYSE: PFE) with an Overweight and raised the price target from $29.00 to $31.00.

JP Morgan said, "While there were no major surprises in the guidance, management did confirm that they expect share repurchase to reach mid-teens billions of dollars range this year. More importantly, management's comments on the call reinforced our view that a larger split-up of the company remains a real possibility longer-term, something we believe would be a clear upside event for Pfizer shares. Despite the move the stock has had, we continue to see a number of drivers for further upside ranging from new product flow, to additional capital return and accretive bolt-on acquisitions."

Pfizer closed at $27.70 on Tuesday.

Latest Ratings for PFE

DateFirmActionFromTo
May 2017CitigroupDowngradesNeutralSell
Dec 2016GuggenheimInitiates Coverage OnNeutral
Nov 2016BarclaysUpgradesEqual-WeightOverweight

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Price Target Analyst Ratings

 

Related Articles (PFE)

View Comments and Join the Discussion!